BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 2996246)

  • 1. [Immunoglobulin A serum antibodies against the capsid antigen of Epstein-Barr virus in the differential diagnosis and follow-up of nasopharyngeal cancer].
    Pavelka R; Popow-Kraupp T; Radaszkiewicz T
    Wien Klin Wochenschr; 1985 Jul; 97(14):588-95. PubMed ID: 2996246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC).
    Liu MT; Yeh CY
    Radiat Med; 1998; 16(2):113-7. PubMed ID: 9650898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
    Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The reliability of IgA antibody to Epstein-Barr virus (EBV) capsid antigen as a test for the diagnosis of nasopharyngeal carcinoma (NPC).
    Levine PH; Pearson GR; Armstrong M; Bengali Z; Berenberg J; Easton J; Goepfert H; Henle G; Henle W; Heffner D; Huang A; Hyams VJ; Lanier A; Neel HB; Pilch B; Pointek N; Taylor W; Terebelo H; Weiland L
    Cancer Detect Prev; 1981; 4(1-4):307-12. PubMed ID: 6299561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analyses of the prognostic significance of the Epstein-Barr virus transactivator ZEBRA protein and diagnostic value of its two synthetic peptides in nasopharyngeal carcinoma.
    Dardari R; Menezes J; Drouet E; Joab I; Benider A; Bakkali H; Kanouni L; Jouhadi H; Benjaafar N; El Gueddari B; Hassar M; Khyatti M
    J Clin Virol; 2008 Feb; 41(2):96-103. PubMed ID: 18024156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nasopharyngeal carcinoma: the diagnostic value of the antibody-dependent, cellular cytotoxicity test and of EBV serology.
    Faggioni A; Corradini C; Venanzoni M; Cardi G; Bevere F; Barile G; Zompetta C; Frati L
    J Exp Pathol; 1987; 3(4):471-7. PubMed ID: 2842480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Demonstration of IgG- and IgA-antibodies against Epstein-Barr virus-associated antigens with a microtiter enzyme immunoassay system. The determination of serum antibodies against the viral capsid antigen and the early antigen complex in the sera of tumor and infectious mononucleosis patients].
    Dölken G; Bitzer M; Bross KJ; Brugger W; Boldt C; Hirsch FW; Weitzmann U; Löhr GW
    Dtsch Med Wochenschr; 1984 Nov; 109(48):1837-43. PubMed ID: 6094138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia.
    Karray H; Ayadi W; Fki L; Hammami A; Daoud J; Drira MM; Frikha M; Jlidi R; Middeldorp JM
    J Med Virol; 2005 Apr; 75(4):593-602. PubMed ID: 15714486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of IgG and IgA type antibodies to capsid and early antigens of the Epstein-Barr virus in the diagnosis of nasopharyngeal carcinoma].
    Mendoza J; Rojas A; de la Rosa M; Amador JM; Expósito J; Esquivias J
    Med Clin (Barc); 1991 Nov; 97(16):609-11. PubMed ID: 1662737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma.
    Chang KP; Hsu CL; Chang YL; Tsang NM; Chen CK; Lee TJ; Tsao KC; Huang CG; Chang YS; Yu JS; Hao SP
    Oral Oncol; 2008 Aug; 44(8):784-92. PubMed ID: 18206420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein Barr virus (EBV) antibodies in the diagnosis of NPC--comparison between IFA and two commercial ELISA kits.
    Chan SH; Soo MY; Gan YY; Fones-Tan A; Sim PS; Kaur A; Chew CT
    Singapore Med J; 1998 Jun; 39(6):263-5. PubMed ID: 9803815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, tonsillar carcinoma and control groups.
    Oberender H; Nowak R; Donner A; Kunkel M; Gärtner L; Scholtz HJ
    Acta Virol; 1983 May; 27(3):277-81. PubMed ID: 6138990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histological types of nasopharyngeal carcinoma as compared to EBV serology.
    Krueger GR; Kottaridis SD; Wolf H; Ablashi DV; Sesterhenn K; Bertram G
    Anticancer Res; 1981; 1(4):187-94. PubMed ID: 6285799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of specific Epstein-Barr virus IgA and elevated IgG antibodies to viral capsid antigens in nasopharyngeal carcinoma patients.
    Hadar T; Rahima M; Kahan E; Sidi J; Rakowsky E; Sarov B; Sarov I
    J Med Virol; 1986 Dec; 20(4):329-39. PubMed ID: 3025351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus seroepidemiology in China.
    Zeng Y; Pi GH; Deng H; Zhang JM; Wang PC; Wolf H; De Thé G
    AIDS Res; 1986 Dec; 2 Suppl 1():S7-15. PubMed ID: 3030349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum anti-EBV IgA is inversely related to tumor infiltration by surface IgA positive lymphocytes in nasopharyngeal carcinoma.
    Gunvén P; Klein G; Henle W; Henle G; Forsby N
    Biomed Pharmacother; 1983; 37(1):41-4. PubMed ID: 6311307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Significance of detection of serum sialic acid and Epstein-Barr virus VCA-IgA in diagnosis and monitoring radiotherapy effectiveness in nasopharyngeal carcinoma patients].
    Jiang LN; Dai LC; He JF; Chen YW; Ma ZH
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Jun; 20(2):30-2. PubMed ID: 16816858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Gene engineering EB virus membrane antigen in detection of MA-IgA antibody--comparison with VCA-IgA and EA-IgA antibodies].
    Liu MZ
    Zhonghua Zhong Liu Za Zhi; 1990 Jul; 12(4):288-90. PubMed ID: 2176967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of combined determinations of Epstein-Barr virus antibodies for nasopharyngeal carcinoma assessed with receiver operating characteristic curve based on logistic regression].
    Cai YL; Zheng YM; Cheng JR; Li J; Mo YK; Zhong QY
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Oct; 23(5):384-7. PubMed ID: 20387494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proper use of serum antibody titres against Epstein-Barr virus in nasopharyngeal carcinoma: IgA/virus capsid antigen for diagnosis and EBV-related nuclear antigen-2 for follow-up.
    Shimakage M; Dezawa T; Chatani M
    Acta Otolaryngol; 2000 Jan; 120(1):100-4. PubMed ID: 10779195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.